AC
ELTX icon

Armistice Capital’s Elicio Therapeutics ELTX Stock Holding History

Armistice Capital’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$411K – 282
2024
Q2 		$411K Buy
+100,000
New +$846K 0.01% 183

Other funds holding ELTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Armistice Capital's ELTX Position: Q3 2024 in Review

Armistice Capital sold out of Elicio Therapeutics (ELTX) in Q3 2024, closing a stake of 100,000 shares — an estimated $411K sold.

Armistice Capital first reported a position in ELTX in Q2 2024 and held it in 1 quarter. The position peaked at $411K in Q2 2024. 18 funds tracked by Wall St. Rank hold ELTX as of Q3 2024.

  • Armistice Capital reported no remaining Elicio Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 100,000 Elicio Therapeutics shares in Q3 2024, an estimated $411K.
  • Armistice Capital first reported a position in Elicio Therapeutics in Q2 2024 and held it in 1 quarter.
  • Armistice Capital's Elicio Therapeutics position peaked at $411K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.